| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/14/2002 | WO2002020023A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/14/2002 | WO2002020021A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| 03/14/2002 | WO2002020020A1 Exemestane as chemopreventing agent |
| 03/14/2002 | WO2002020017A2 Use of ectoin or ectoin derivatives for stabilizing p53 |
| 03/14/2002 | WO2002020000A2 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 03/14/2002 | WO2002019972A2 Stabilized ascorbic acid solutions |
| 03/14/2002 | WO2001096564A3 Hla-g (hla-g7) isoform and its applications |
| 03/14/2002 | WO2001082909A3 2-acyl indol derivatives and their use as anti-tumour agents |
| 03/14/2002 | WO2001079502A3 Vectors for gene therapy |
| 03/14/2002 | WO2001078655A3 Methods and compositions for heat shock protein mediated immunotherapy of melanoma |
| 03/14/2002 | WO2001078651A3 Method for treating neoplasmin with topoisomase i inhibitor |
| 03/14/2002 | WO2001077358A3 Herpes viruses for immune modulation |
| 03/14/2002 | WO2001077147A3 New bromodomain protein |
| 03/14/2002 | WO2001076644A3 Lipid-based systems for targeting diagnostic agents |
| 03/14/2002 | WO2001076555A3 Lipid-based drug delivery systems for topical application |
| 03/14/2002 | WO2001074790A3 Novel compounds for enhancing chemotherapy |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001059129A3 Mammalian secreted group iii phospholipase a2 |
| 03/14/2002 | WO2001058921A9 Methods and compositions for generating angiostatin |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055392A3 Nuclear hormone receptors |
| 03/14/2002 | WO2001055358A3 Phosphodiesterases |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001054707A3 Modification of surface proteins by aminopeptidase inhibitors |
| 03/14/2002 | WO2001052826A3 Novel podophyllotoxin compositions |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2001048162A3 Method for the production of vitamin a |
| 03/14/2002 | WO2001044497A3 Protein kinase regulation |
| 03/14/2002 | WO2001036684A3 Mammalian toxicological response markers |
| 03/14/2002 | WO2001027267A3 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions |
| 03/14/2002 | WO2001023572A3 Polynucleotides and polypeptides encoded thereby |
| 03/14/2002 | WO2001020031A3 Polymorphisms in a klotho gene |
| 03/14/2002 | WO2001002018A3 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000058483A9 Protozoan expression system |
| 03/14/2002 | WO2000056899A9 Dsp-2 dual-specificity map kinase phosphatase |
| 03/14/2002 | WO2000053742A9 Polynucleotides and proteins encoded thereby |
| 03/14/2002 | WO1997003998A9 Modulators of the function of fas receptors and other proteins |
| 03/14/2002 | US20020032326 Treating mammalian leukemia; lung carcinoma; colon adenocarcinoma malignant melanoma; assaying the human cytochrome CYP3A4 metabolism of ecteinascidin 743 |
| 03/14/2002 | US20020032324 Process for the preparation of endotoxin-free or endotoxin-depleted nucleic acids and/or oligonucleotides for gene therapy |
| 03/14/2002 | US20020032312 Recombinant multispecific molecule comprising an anti-Fc receptor portion and an anti-target portion. |
| 03/14/2002 | US20020032306 Cyclopeptide derivatives |
| 03/14/2002 | US20020032229 Novel compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032214 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 03/14/2002 | US20020032213 Macrolides |
| 03/14/2002 | US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen |
| 03/14/2002 | US20020032208 Chemical compounds |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032202 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032190 Contacting host with a cephalotaxine and an antiproliferative agent such as an alkylating agent, an intercalating agent, a metal coordination complex, a nucleoside, a nucleic acid enyme or protein inhibitor to modulate cell proliferation |
| 03/14/2002 | US20020032181 For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated |
| 03/14/2002 | US20020032179 Inhibiting the hyperproliferation of malignant or neoplastic cells by treating the cells with an antiproliferative amount of 1 alpha ,24(S)-dihydroxyvitamin D2 the cells being cancers of the lung, neck and head, pancreas, endometrium, bladder |
| 03/14/2002 | US20020032165 Microspheres and adjuvants for DNA vaccine delivery |
| 03/14/2002 | US20020032158 Having anti-tumor activity and immunostimulating activity |
| 03/14/2002 | US20020032151 Using an agent which promotes tyrosine protein dephosphorylation in the preparation of a medicament for reducing permeability of a physiological barrier such as the blood-brain barrier |
| 03/14/2002 | US20020031823 Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene |
| 03/14/2002 | US20020031531 Immunotherapy for lung or urogenital cancer |
| 03/14/2002 | US20020031520 Prevention and treatment of hepatocellular cancer |
| 03/14/2002 | US20020031515 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| 03/14/2002 | US20020031508 Administering inducer of P-selectin activity such that hemostasis occurs |
| 03/14/2002 | US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent |
| 03/14/2002 | US20020031505 Antitumor compositions containing taxane derivatives |
| 03/14/2002 | US20020031499 Defective recombinant adenoviruses expressing cytokines for antitumor treatment |
| 03/14/2002 | US20020031475 To give better sensitivity |
| 03/14/2002 | DE10043456A1 Verwendung von Ectoin oder Ectoin-Derivaten zur Stabilisierung von p53 Use of ectoine or ectoine derivatives for the stabilization of p53 |
| 03/14/2002 | DE10042997A1 Thienopyrimidine Thienopyrimidines |
| 03/14/2002 | DE10041402A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity |
| 03/14/2002 | DE10041217A1 Verwendung von Dihydroboswelliasäuren oder hydrierten Extrakten aus Boswellia zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten körperlichen oder seelischen Zuständen Use of Dihydroboswelliasäuren or hydrogenated extracts of Boswellia for prophylactic and / or therapeutic treatment of unwanted physical or mental conditions |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2422157A1 Inhibitors of serine protease activity of matriptase or mtsp1 |
| 03/14/2002 | CA2422114A1 Novel human cancer/testis antigen and gene thereof |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421760A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421757A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421718A1 Protein tyrosine phosphatase inhibitor |
| 03/14/2002 | CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | CA2421448A1 Hla binding peptides and their uses |
| 03/14/2002 | CA2421445A1 Hla binding peptides and their uses |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421075A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | CA2421041A1 Caveolin peptides and their use as therapeutics |
| 03/14/2002 | CA2420225A1 Hla-a2.1 binding peptides and their uses |
| 03/14/2002 | CA2419983A1 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 03/14/2002 | CA2419590A1 Exemestane as chemopreventing agent |
| 03/14/2002 | CA2417660A1 Vp22 protein/nucleic acid aggregates, uses thereof |